Aptamers: Prospects in therapeutics and biomedicine

Amy C. Yan, Kathryn M. Bell, Megan M. Breeden, Andrew D. Ellington

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Most biopolymer drugs to date have been proteins. However, the ability to select nucleic acid binding species (aptamers) has led to the development of protein inhibitors and modulators that are small, readily synthesized nucleic acids. The techniques for optimizing, stabilizing, and delivering nucleic acid therapies are just beginning to be developed, but the same engineering flexibility that has so far allowed the generation of multiple, high affinity and specificity binding species appears to also apply to the methods for adapting nucleic acids to clinical applications. We review the selection and characterization of various aptamers and their applications to a variety of disease states, and then focus on the hurdles that must be overcome for the use of aptamers as both exogenously delivered drugs and as gene therapies.

Original languageEnglish (US)
Pages (from-to)1802-1827
Number of pages26
JournalFrontiers in Bioscience
Volume10
Issue number2
StatePublished - 2005
Externally publishedYes

Fingerprint

Nucleic Acids
Species Specificity
Gene therapy
Biopolymers
Therapeutics
Pharmaceutical Preparations
Genetic Therapy
Modulators
Proteins

Keywords

  • Aptamers
  • Gene
  • Gene therapy
  • Review
  • Selex
  • Therapeutics
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Yan, A. C., Bell, K. M., Breeden, M. M., & Ellington, A. D. (2005). Aptamers: Prospects in therapeutics and biomedicine. Frontiers in Bioscience, 10(2), 1802-1827.

Aptamers : Prospects in therapeutics and biomedicine. / Yan, Amy C.; Bell, Kathryn M.; Breeden, Megan M.; Ellington, Andrew D.

In: Frontiers in Bioscience, Vol. 10, No. 2, 2005, p. 1802-1827.

Research output: Contribution to journalArticle

Yan, AC, Bell, KM, Breeden, MM & Ellington, AD 2005, 'Aptamers: Prospects in therapeutics and biomedicine', Frontiers in Bioscience, vol. 10, no. 2, pp. 1802-1827.
Yan AC, Bell KM, Breeden MM, Ellington AD. Aptamers: Prospects in therapeutics and biomedicine. Frontiers in Bioscience. 2005;10(2):1802-1827.
Yan, Amy C. ; Bell, Kathryn M. ; Breeden, Megan M. ; Ellington, Andrew D. / Aptamers : Prospects in therapeutics and biomedicine. In: Frontiers in Bioscience. 2005 ; Vol. 10, No. 2. pp. 1802-1827.
@article{4faeb5b7d1d640388f1dd61c61cbccdb,
title = "Aptamers: Prospects in therapeutics and biomedicine",
abstract = "Most biopolymer drugs to date have been proteins. However, the ability to select nucleic acid binding species (aptamers) has led to the development of protein inhibitors and modulators that are small, readily synthesized nucleic acids. The techniques for optimizing, stabilizing, and delivering nucleic acid therapies are just beginning to be developed, but the same engineering flexibility that has so far allowed the generation of multiple, high affinity and specificity binding species appears to also apply to the methods for adapting nucleic acids to clinical applications. We review the selection and characterization of various aptamers and their applications to a variety of disease states, and then focus on the hurdles that must be overcome for the use of aptamers as both exogenously delivered drugs and as gene therapies.",
keywords = "Aptamers, Gene, Gene therapy, Review, Selex, Therapeutics, Treatment",
author = "Yan, {Amy C.} and Bell, {Kathryn M.} and Breeden, {Megan M.} and Ellington, {Andrew D.}",
year = "2005",
language = "English (US)",
volume = "10",
pages = "1802--1827",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Aptamers

T2 - Prospects in therapeutics and biomedicine

AU - Yan, Amy C.

AU - Bell, Kathryn M.

AU - Breeden, Megan M.

AU - Ellington, Andrew D.

PY - 2005

Y1 - 2005

N2 - Most biopolymer drugs to date have been proteins. However, the ability to select nucleic acid binding species (aptamers) has led to the development of protein inhibitors and modulators that are small, readily synthesized nucleic acids. The techniques for optimizing, stabilizing, and delivering nucleic acid therapies are just beginning to be developed, but the same engineering flexibility that has so far allowed the generation of multiple, high affinity and specificity binding species appears to also apply to the methods for adapting nucleic acids to clinical applications. We review the selection and characterization of various aptamers and their applications to a variety of disease states, and then focus on the hurdles that must be overcome for the use of aptamers as both exogenously delivered drugs and as gene therapies.

AB - Most biopolymer drugs to date have been proteins. However, the ability to select nucleic acid binding species (aptamers) has led to the development of protein inhibitors and modulators that are small, readily synthesized nucleic acids. The techniques for optimizing, stabilizing, and delivering nucleic acid therapies are just beginning to be developed, but the same engineering flexibility that has so far allowed the generation of multiple, high affinity and specificity binding species appears to also apply to the methods for adapting nucleic acids to clinical applications. We review the selection and characterization of various aptamers and their applications to a variety of disease states, and then focus on the hurdles that must be overcome for the use of aptamers as both exogenously delivered drugs and as gene therapies.

KW - Aptamers

KW - Gene

KW - Gene therapy

KW - Review

KW - Selex

KW - Therapeutics

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=17244375766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17244375766&partnerID=8YFLogxK

M3 - Article

C2 - 15769669

AN - SCOPUS:17244375766

VL - 10

SP - 1802

EP - 1827

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 2

ER -